Supernus Pharmaceuticals Inc (SUPN)
Gross profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 259,929 | -1 | 205,614 | 177,659 | 243,526 |
| Revenue | US$ in thousands | 661,817 | 607,521 | 673,056 | 560,079 | 500,962 |
| Gross profit margin | 39.28% | -0.00% | 30.55% | 31.72% | 48.61% |
December 31, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $259,929K ÷ $661,817K
= 39.28%
Supernus Pharmaceuticals Inc's gross profit margin has exhibited a fluctuating trend over the past five years. The margin decreased from 48.61% as of December 31, 2020, to 31.72% by December 31, 2021, reflecting a significant decline in profitability. This downward trend continued into the following year, dropping to 30.55% by December 31, 2022.
A notable anomaly occurred as of December 31, 2023, with the gross profit margin recording -0.00%, suggesting a breakeven point where costs equaled revenue. It is essential to investigate the factors contributing to this zero gross profit margin to understand the underlying reasons.
However, there seems to have been a recovery in profitability in the most recent year, with the gross profit margin increasing to 39.28% as of December 31, 2024. This improvement indicates a potential rebound in financial performance.
Overall, the erratic nature of Supernus Pharmaceuticals Inc's gross profit margin underscores the importance of closely monitoring cost management and revenue generation strategies to maintain and enhance profitability levels in the future.
Peer comparison
Dec 31, 2024